Sol-Gel Technologies to Report Second Quarter 2020 Financial Results on August 6, 2020
07/29/2020 - 07:05 AM
NESS ZIONA, Israel, July 29, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, will report second quarter 2020 financial results on Thursday, August 6, 2020 at 7:05 AM ET.
About Sol-Gel Technologies
Sol-Gel is a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Sol-Gel leverages its proprietary microencapsulation technology platform for Twyneo, for the treatment of acne vulgaris, and Epsolay, for the treatment of papulopustular rosacea. The Company’s pipeline also includes SGT-210, an early-stage topical epidermal growth factor receptor inhibitor, erlotinib, for the treatment of palmoplantar keratoderma, and preclinical assets tapinarof and roflumilast. For additional information, please visit www.sol-gel.com .
For further information, please contact:
Sol-Gel Contact: Gilad Mamlok Chief Financial Officer +972-8-9313433
Investor Contact: Lee M. Stern Solebury Trout +1-646-378-2922lstern@soleburytrout.com
Source: Sol-Gel Technologies Ltd.
SLGL Rankings
#5200 Ranked by Stock Gains
SLGL Stock Data
Industry
Medicinal and Botanical Manufacturing
Sector
Manufacturing
Tags
Health Technology, Pharmaceuticals: Major, Manufacturing, Medicinal and Botanical Manufacturing
Country
Israel
City
7 Golda Meir
About SLGL
sol-gel is a clinical-stage specialty pharmaceutical company focused on developing and commercializing topical dermatological drug products. our lead product candidates, vered for the treatment of papulopustular rosacea and twin and sirs-t for the treatment of acne vulgaris (“acne”) are based upon our proprietary microencapsulation delivery system. this technology consists of microcapsules made of silica. based on our pre-clinical and clinical data, this delivery system should enable us to develop and commercialize dermatological drug products that are more effective and/or have fewer side effects than currently marketed drugs. our silica-based delivery system improves the tolerability of topical dermatological drug products by entrapping drug substances in porous silica microcapsules. this creates a protective barrier between the drug substance and the skin and controls the release rate of the drug substance. our delivery system also enables to produce novel fixed-dose combinations th